Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=24718366
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\24718366
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Hum+Vaccin+Immunother
2014 ; 10
(6
): 1449-56
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Vaccine against norovirus
#MMPMID24718366
Tan M
; Jiang X
Hum Vaccin Immunother
2014[]; 10
(6
): 1449-56
PMID24718366
show ga
Noroviruses (NoVs) are important pathogens causing epidemic acute gastroenteritis
affecting millions of people worldwide. Due to the inability to cultivate NoVs,
current NoV vaccine development relies on bioengineering technologies to produce
virus-like particles (VLPs) and other subviral particles of NoVs as subunit
vaccines. The first VLP vaccine has reached phase II clinical trials and several
others are under development in pre-clinical research. Several subviral complexes
made from the protruding (P) domains of NoV capsid share common features of easy
production, high stability and high immunogenicity and thus are candidates for
low cost vaccines. These P domain complexes can also be used as vaccine platforms
to present foreign antigens for potential dual vaccines against NoVs and other
pathogens. Development of NoV vaccines also faces other challenges, including
genetic diversity of NoVs, limit understanding of NoV immunology and evolution,
and lack of an efficient NoV animal model for vaccine assessment, which are
discussed in this article.
|Caliciviridae Infections/*epidemiology/*prevention & control
[MESH]
|Clinical Trials, Phase II as Topic
[MESH]
|Drug Discovery/*trends
[MESH]
|Gastroenteritis/epidemiology/prevention & control
[MESH]